Hospital resources for urokinase/recombinant tissue-type plasminogen activator therapy for acute stroke in Beijing.
BACKGROUND
We focus on the current resource level for UK/rt-PA therapy in hospitals in Beijing to design strategies for improving treatment for stroke patients.


METHODS
The data were collected through surveys of 124 grade II or higher hospitals in Bejing, which provide stroke treatment, from July to September 2006.


RESULTS
Of the surveyed hospitals, 50% and 92.6% were capable in providing intravenous UK/rt-PA treatment and head CT service, respectively. Eight (7.4%) hospitals have specialized stroke units and 106 (98.1%) hospitals have EDs. We found significant differences between hospitals that can provide UK/rt-PA therapy and the hospitals that cannot in the levels of specialists and clinical care capacity as follows: CT (100% vs 85.2%; P = 0.01), CTA (46.3% vs 22.2%; P = .014), MRI (66.7% vs 22.2%; P = .000), MRA (57.4% vs 20.4%; P = .000), DWI (48.1% vs 9.3%; P = .000), PWI (31.5% vs 5.6%; P = .001), DSA (63.0% vs 25.9%; P = .000), neurologists (100% vs 79.6%; P = .001), neurosurgeons (75.9% vs 44.4%; P = .002), carotid stenting (33.3% vs 5.6%; P = .000), stroke unit (14.8% vs 0%; P = .01), and acute stroke care system (31.5% vs 0%; P = .000).


CONCLUSIONS
The thrombolysis treatment facilities in Beijing are not sufficient. Hospitals in Beijing should organize stroke-related medical sources.
Wang
Yilong
Y
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China. yilong528@gmail.com
Wu
Di
D
Zhao
Xingquan
X
Ma
Ruihua
R
Guo
Xiangping
X
Wang
Chunxue
C
Liu
Liping
L
Zhao
Weijiang
W
Wang
Yongjun
Y
D000208:Acute Disease; D000328:Adult; D000368:Aged; D002681:China; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data*; D004638:Emergency Treatment; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D015276:Health Care Rationing / Q000706:statistics & numerical data; D019538:Health Care Surveys; D006295:Health Resources / Q000600:supply & distribution*; D006757:Hospital Units / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D040841:Resource Allocation / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*; D000078329:Workforce
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator